Antibody Formulation Using Trehalose for Long-Term Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic proteins face challenges in maintaining long-term stability due to structural and functional instability, which can lead to degradation and loss of efficacy and safety, necessitating the development of formulations that enhance stability under diverse conditions.
Innovation Solution
Formulations comprising an antibody, a buffer, an amino acid, and trehalose at a pH between 5.0 to 7.0, which provide enhanced stability at various temperatures and protect against aggregation and degradation, including during low pH conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a formulation is designed to maintain antibody stability under diverse storage conditions, then long-term stability is improved, but formulation complexity increases
Solution Approach 1:
The formulation uses a composite system comprising multiple excipients (trehalose, amino acids, buffers, surfactants) working synergistically to stabilize antibodies. Trehalose provides glass matrix formation and molecular shielding, amino acids prevent aggregation through electrostatic repulsion, buffers maintain pH stability, and surfactants prevent surface adsorption. This composite approach achieves comprehensive stability protection while managing formulation complexity through established pharmaceutical excipient combinations.
Solution Approach 2:
The formulation optimizes multiple parameters simultaneously: pH (5.0-7.0 range), ionic strength, water activity, and glass transition temperature. By controlling these parameters within specific ranges, the formulation achieves enhanced antibody stability across diverse storage conditions including temperature variations, freeze-thaw cycles, and extended storage periods.
2Reliability
If formulation components are added to protect against degradation, then antibody efficacy is improved, but manufacturing cost increases
Solution Approach 1:
The formulation employs self-stabilizing mechanisms where excipients automatically perform protective functions without external intervention. Trehalose forms a glass matrix that passively protects antibody structure, amino acids provide continuous electrostatic shielding against aggregation, and buffers autonomously maintain pH within the optimal range. These self-service properties reduce the need for complex manufacturing controls and expensive stabilization technologies.
Solution Approach 2:
The formulation uses cost-effective, readily available pharmaceutical excipients (trehalose, common amino acids like arginine or histidine, standard buffers) rather than expensive proprietary stabilizers. These conventional materials provide adequate protection for the intended shelf life while keeping manufacturing costs reasonable and scalable.
3Duration of action of stationary object
If storage conditions are optimized for stability, then antibody activity is preserved, but storage flexibility is reduced
Solution Approach 1:
The formulation is designed with dynamic stability properties that adapt to varying storage conditions. The glass matrix formed by trehalose provides structural protection across a wide temperature range, while the buffer system dynamically adjusts to maintain pH stability during temperature fluctuations and freeze-thaw cycles. This dynamic response allows the antibody to remain stable under diverse storage scenarios including refrigeration, freezing, and ambient temperature storage.
Solution Approach 2:
The formulation achieves multi-functional stability protection: trehalose simultaneously provides glass matrix formation, molecular shielding, and freeze protection; amino acids prevent both aggregation and chemical degradation; buffers maintain pH across temperature variations. This universal protective approach enables the formulation to maintain antibody activity under multiple storage conditions without requiring condition-specific modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations maintain antibody stability and biological activity over extended periods, reducing production and treatment costs while ensuring safety and efficacy.
Implementation Method 1
trehalose, having a pH between 5.0 to 7.0
Implementation Method 2
protecting it from degradation
Implementation Method 3
a buffer, an amino acid and trehalose, having a pH between 5.0 to 7.0
Implementation Method 4
an amino acid and trehalose
Data Source
AI summary
The disclosure relates to a formulation comprising an antibody, a buffer, an amino acid and trehalose, having a pH between 5.0 to 7.0. The formulation of the disclosure finds application in the prevention and/or treatment of a disease which requires neutralization of the antigen which is targeted by the antibody present in the formulation. The disclosure also relates to a method for preparing a stabilized antibody-containing composition.